Clinical Trial: Efficacy of New Trio Combination for Melasma

U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07676994) titled 'Efficacy of New Trio Combination for Melasma' on June 24.

Brief Summary: The goal of this clinical trial is to learn if the drug New Trio Combination (0.1% isobutylamido-thiazolyl-resorcinol, 0.1% retinoic acid and 0.1% dexamethasone) works to treat melasma. It will also learn about the safety of drug. This drug lowers the pigmentation severity by measuring modified Melasma Area and Severity Index (mMASI) reduction by up to 50%. The possible side effects of this drug are erythema and burning. We will compare this drug to kligman's formula (5% hydroquinon, 0.1% retinoic acid and 0.1% dexamethasone) to see if New Trio Combination works...